DTech Liquidating

DTech Liquidating FCF/Net Income

Delisted

The Free Cash Flow to Net Income Ratio of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 77.20 %. In the previous year, Free Cash Flow to Net Income Ratio was 84.48 % — a change of -8.62% (lower).

FCF/Net Income

77.20 %

YoY

-8.62%

Last updated:

Free Cash Flow to Net Income Ratio of DTech Liquidating is 2023 77.20 % . Free Cash Flow to Net Income Ratio of DTech Liquidating was 2022 84.48 % . It decreases by -8.62% lower compared to the previous year.

The DTech Liquidating FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2017
160.87 USD
Jan 1, 2018
-59.46 USD
Jan 1, 2019
91.42 USD
Jan 1, 2020
83.63 USD
Jan 1, 2021
82.75 USD
Jan 1, 2022
84.48 USD
Jan 1, 2023
77.20 USD
The DTech Liquidating FCF/Net Income history
YEARFCF/Net IncomeYoY
77.20 %-8.62%
84.48 %+2.08%
82.75 %-1.05%
83.63 %-8.51%
91.42 %-253.75%
-59.46 %-136.96%
160.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Free Cash Flow to Net Income Ratio of DTech Liquidating is 77.20 % in 2023.

Free Cash Flow to Net Income Ratio of DTech Liquidating changed from 84.48 % to 77.20 %, representing a -8.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — DTech Liquidating

All Key Metrics — DTech Liquidating